Clinical Study Results Sanofi Pharma, including Sanofi Genzyme

Information about sponsored clinical trials and result information are provided for informational purposes only and are not intended to promote any product or use. Clinical study results are intended to report the results of the study that were known at the time of the study's completion. The results therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available. Physicians and patients should refer to the current approved product labeling for information on approved indications in their country.
This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional.

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Clinical study results Sanofi pharma, including Sanofi Genzyme – Letter F

Generic Name Trade Name Condition Study Code Study Name Access to study Access to results
FATTY ACID AMIDE HYDROLASE INHIBITOR Not marketed Cancer pain ACT11705 NA EudraCT: 2011-002557-56
FATTY ACID AMIDE HYDROLASE INHIBITOR Not marketed Major Depressive Disorder DFI10560 FIDELIO EudraCT: 2008-001718-26
FEDRATINIB Not marketed Myelofibrosis ARD12888 NA NCT01692366
FEDRATINIB Not marketed Myelofibrosis ARD12888 NA NCT01692366
FEDRATINIB Not marketed Hematopoietic Neoplasm ARD12042 NA NCT01420783
FEDRATINIB Not marketed Hematopoietic Neoplasm ARD11936 NA NCT01420770
FEDRATINIB Not marketed Neoplasm malignant TES13519 NA NCT01836705
FEDRATINIB Not marketed Hematopoietic Neoplasm ARD12181 JAKARTA2 NCT01523171
FEDRATINIB Not marketed Myelofibrosis EFC12153 JAKARTA EudraCT: 2011-001897-25
FEDRATINIB Not marketed Solid Tumor INT12497 NA NCT01585623
FEDRATINIB Not marketed Renal Impairment POP13449 NA NCT01763190
FEDRATINIB Not marketed Hepatic Impairment POP13450 NA NCT01762462
FEXOFENADINE HYDROCHLORIDE Allegra Urticaria M016455_4001 NA NA
FEXOFENADINE HYDROCHLORIDE Allegra Urticaria M016455A_4121 NA NA
FEXOFENADINE HYDROCHLORIDE Allegra Rhinitis, Seasonal M016455_4124 NA NCT00636870
FEXOFENADINE HYDROCHLORIDE Allegra Cognition M016455A_4139 NA NCT00637455
FEXOFENADINE HYDROCHLORIDE Allegra Urticaria M016455A_4143 NA NA
FEXOFENADINE HYDROCHLORIDE Allegra Urticaria M016455A_4144 NA NCT00547768
FEXOFENADINE HYDROCHLORIDE Allegra Seasonal allergy M016455A_4145 NA NCT00637585
FEXOFENADINE HYDROCHLORIDE Allegra Seasonal allergy M016455A_4146 NA NCT00638118
FEXOFENADINE HYDROCHLORIDE Allegra Cat allergy symptoms M016455A_4148 NA NCT00637884
FEXOFENADINE HYDROCHLORIDE Allegra Seasonal Allergic Rhinitis M016455A_4149 NA NCT00637611
FEXOFENADINE HYDROCHLORIDE Allegra Seasonal Allergic Rhinitis M016455C_4001 NA NCT00741897
FEXOFENADINE HYDROCHLORIDE Allegra Rhinitis Perennial SFY10717 NA NCT01244217
FEXOFENADINE HYDROCHLORIDE Allegra Atopic Dermatitis SFY10718 NA NCT01244230
FEXOFENADINE HCl - PSEUDOEPHEDRINE HCl combination Allegra-D Rhinitis Perennial EFC11243 NA NCT01306721
FEXOFENADINE HCl - PSEUDOEPHEDRINE HCl combination Allegra-D Allergic Rhinitis FEXHYL06934 NA NCT02175485
FLUOROURACIL Carac Keratosis DL6025-0201 NA NCT00377273
FRESOLIMUMAB Glomerulosclerosis GC1008FSGS03110 NA EudraCT: 2012-002365-35
FUROSEMIDE Lasix, Eutensin, Lasilix Chronic Renal Failure FUROSL06121 NA NCT01724788

References:
*These study results were previously posted on GenzymeClinicalResearch.com
**This link replaces the same summary that was previously posted